← ANALYST RATINGS · TIPRANKS

CareDx (CDNA): analyst forecast and price target

$64.00 −4.01% close 16.10.26 · market cap $3.3B · Healthcare · Medical - Diagnostics & Research IWM 0.12%
Price targets and ratings of

Analyst consensus

Moderate Buy

3 Buy3 Hold0 Sell

Ratings of 6 analysts in the last 3 months

12-month forecast

$54.00−15.6% downside

Based on 6 price targets given in the last 3 months, the average target is $54.00, the highest $74.00, the lowest $21.00. The average is −15.6% from the last price of $64.00.

$20.00$40.00$60.00Jan 26AprJulOctJan 27AprJulOctHigh$74.00Average$54.00Low$21.00
Highest target $74.00 Average target $54.00 Lowest target $21.00
AnalystFirmPrice target RatingUpsideAction Date Move vs SPY
Mark Massaro★★★★★★★★★★#2635 · hits 40% · avg +5.7% BTIG $60.00 → $74.00+23.3% Buy +15.6% Reiterated 24.09.26on TipRanks 07:15 +13.1%next day +3.2% · 5 days +8.3%
Kyle Mikson CFA★★★★★★★★★★#2814 · hits 38% · avg +5.9% Canaccord Genuity $65.00 Buy +1.6% Initiated 02.09.26on TipRanks 06:00 +0.8%next day −0.5% · 5 days +1.8%
William Bonello★★★★★★★★★★#152 · hits 66% · avg +35.0% Craig-Hallum $35.00 → $64.00+82.9% Buy 0.0% Upgrade 03.08.26on TipRanks 07:15 +8.0%next day −3.4% · 5 days −3.7%
Matt Larew★★★★★★★★★★#816 · hits 63% · avg +19.3% William Blair — Hold — Assigned 03.08.26on TipRanks 04:55 +8.0%next day −3.4% · 5 days −3.7%
Yi Chen★★★★★★★★★★#10518 · hits 41% · avg −1.0% H.C. Wainwright $46.00 Hold −28.1% Reiterated 31.07.26on TipRanks 06:50 +14.0%next day +8.0% · 5 days +3.3%
Unknown Analyst Wells Fargo $21.00 Hold −67.2% Reiterated 29.07.26on TipRanks Jul 31 01:06 +0.6%next day +5.9% · 5 days +23.0%
Unknown Analyst Stephens $28.00 Buy −56.2% Reiterated 29.04.26on TipRanks 09:20 −5.1%next day −0.9% · 5 days −2.4%

The latest rating of each analyst in the last 12 months, as TipRanks lists them. Every rating kept, earlier ones included

Best analysts covering CareDx

TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.

Most accurate

3 months Mark Massaro★★★★★★★★★★BTIG · #2635
Hits 40%198 of 498 Average return +5.7%
1 year William Bonello★★★★★★★★★★Craig-Hallum · #152
Hits 66%150 of 226 Average return +35.0%
2 years Mark Massaro★★★★★★★★★★BTIG · #2635
Hits 40%198 of 498 Average return +5.7%

Most profitable

3 months William Bonello★★★★★★★★★★Craig-Hallum · #152
Hits 66%150 of 226 Average return +35.0%
1 year Mark Massaro★★★★★★★★★★BTIG · #2635
Hits 40%198 of 498 Average return +5.7%
2 years Mark Massaro★★★★★★★★★★BTIG · #2635
Hits 40%198 of 498 Average return +5.7%

How the average price target moved

The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $54.00 at a price of $65.00 (−16.9%); now: $54.00 at $64.00 (−15.6%).

$50.00$60.00$70.00Sep 15Oct 1Oct 15Top analysts$67.67Average target$54.00Price$64.00

PriceAverage targetTop analysts’ target

Recommendation trend

051015234Oct 25132Nov23Dec36Jan 26129Feb129Mar1313Apr29May210Jun18Jul38Aug57Sep42Oct

Strong BuyBuyHoldSell

Rating05.2606.2607.2608.2609.2610.26
Strong Buy000000
Buy221354
Hold9108872
Sell000000

Earnings and sales forecast

Next report: 29.10.26 (Q3 2026, date not confirmed)

Earnings per share

Next quarter’s EPS estimate — $0.26 (from $0.24 to $0.27). Last quarter: $0.37.

Sales

Next quarter’s sales estimate — $122M (from $121M to $124M). Last quarter: $132M.

Best top-analyst consensus in the sector · Healthcare

AXGNAxoGen
MDWDMediwound
OCULOcular Therapeutix
OVIDOvid Therapeutics
ZYMEZymeworks
About CareDx
  • CEO: John Walter Hanna Jr.
  • Employees: 763
  • 8000 Marina Boulevard, Brisbane, CA, 94005, US
  • www.caredx.com

CareDx, Inc. is a global innovator specializing in the discovery, development, and commercialization of diagnostic and management tools designed for transplant recipients and their healthcare providers. The company's extensive portfolio features a range of specialized diagnostic solutions for organ monitoring, including: AlloSure Kidney, AlloSure Heart, and AlloSure Lung: Advanced tests employing donor-derived cell-free DNA (dd-cfDNA) technology to assess the health of kidney, heart, and lung transplants, respectively. AlloMap Heart: A gene expression-based solution specifically for heart transplant patients. AlloSeq cfDNA: A broader surveillance tool to measure dd-cfDNA levels in the blood. CareDx also provides cutting-edge human leukocyte antigen (HLA) typing technologies, such as TruSight HLA, an NGS-based high-resolution typing solution; Olerup SSP, which uses sequence-specific primer technology for HLA allele typing; QTYPE for precise HLA typing; and AlloSeq Tx, another high-resolution HLA typing offering. For stem cell transplant recipients, the company offers AlloSeq HCT for chimerism testing. Beyond diagnostics, CareDx develops vital software and digital platforms to streamline transplant patient management. These include Ottr, a dedicated transplant patient management software; XynQAPI, focused on transplant quality tracking and waitlist management; and AlloCare, a mobile application serving as a patient-centric resource for those who have undergone transplantation. The company distributes its products directly to clients, as well as through a network of third-party distributors and sub-distributors. CareDx has forged significant partnerships, including a licensing agreement with Illumina, Inc. for the distribution, development, and commercialization of next-generation sequencing (NGS) products and technologies. Additionally, it collaborates with Cibiltech SAS to commercialize iBox, a software designed for the predictive analysis of kidney allograft loss po

Data from the stock’s TipRanks forecast page, read 94 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗